Over the last two decades, the Pharmaceutical/Biotech industry has undergone radical changes. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing, IQ4I estimates that ~15% of the pharmaceutical/biotech R&D spending goes into drug discovery.
Almost all the major Pharmaceutical/biotech companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Now-a-days, the big pharma relies more on CRO’s for drug discovery capabilities to stock up their pipelines
The global pharmaceutical outsourcing market was estimated to be $XX billion in 2015 and of that a little less than fifty percent accounted for CRO’s. IQ4I estimates that the global drug discovery based services to be $XX billion in 2015 and rest accounts for biology-related service and clinical services. Current R&D outsourcing penetration is estimated to be ~ X percent of the global pharmaceutical and biotech industry spending but poised to grow at CAGR of X% percent in the coming years.
This report provides comprehensive insights on the global drug discovery outsourcing market. The report covers all segments, global trends and emerging strategies of the outsourcing market related to drug discovery. Major Drug Discovery Outsourcing (DDO) players included in the report are Evotec, Charles River Laboratories (CRL), Pharmaceutical Product Development (PPD), WuxiApptec, ChemPartner, Syngene, Aurigene, Jubilant Biosys, Advinus, GVK Biosciences, TCG Lifesciences and AMRI.
This report caters to the need of Contract research organizations, Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Service providers and other associated stake holders to identify and analyze the potential of the DDO market. The report also provides insights on customer base, number of deals between CRO’s and Pharmaceutical /biotech firms, global FTE rates, employee strength & number of companies, revenue per employee of major players, therapeutic area gap analysis and successful research collaboration outcomes of selected CRO’s and Sponsors, which are likely to have an impact on the DDO market in the foreseeable future.
This report covers in-depth analysis of major players by therapeutic area of focus, capabilities, geographic presence, business models, financials, collaborations, acquisitions, various marketing strategies adopted along with insightful analysis on conferences, clusters and match making websites.
Table of Contents
2 Market Analysis
2.1 Research Methodology
2.2 Forecasting Model
2.3 Market Dynamics
2.4 Market Sizing
2.5 Emerging Trends & Strategies
3 Business Overview
3.1 Business Models
3.2 Business Evolution
3.4 DD Indicators
3.5 Pharma R&D EXP & Intensity
4 Competitor Analysis
4.1 Therapeutic Area Matrix
4.2 Global Fte Rates
4.3 Regional Revenues Vs FTE
4.4 Key players (Revenue per Employee, Customers, Deals & Ta Pie Chart, Collaboration Outcomes)
5 Leading Players
5.3 Therapeutic Area
5.4 Business Models
6 Marketing Strategies
6.1.1 Conferences -2014, 2015, 2016
6.1.2 Conference Analysis- 2014-15
6.2 Match Making Websites
6.3 Virtual Pharmaceuticals
6.4 Online RPFS
6.5 Networking Websites
6.7 Other Marketing Strategies
6.7.1 Website Rankings, LinkedIn Followers, Google Search Volumes
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349